601 related articles for article (PubMed ID: 19100899)
21. Sirolimus: new preparation. No tangible advance in renal transplantation.
Prescrire Int; 2002 Dec; 11(62):165-6. PubMed ID: 12469693
[TBL] [Abstract][Full Text] [Related]
22. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
Kahan BD
Transplantation; 2001 Jun; 71(11 Suppl):SS52-7. PubMed ID: 11583490
[TBL] [Abstract][Full Text] [Related]
23. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Nashan B
Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
Cowan PA; Heizer KE
Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
[TBL] [Abstract][Full Text] [Related]
25. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
Guerra G; Srinivas TR; Meier-Kriesche HU
Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
[TBL] [Abstract][Full Text] [Related]
26. The role and value of sirolimus administration in kidney and liver transplantation.
Mehrabi A; Fonouni H; Kashfi A; Schmied BM; Morath Ch; Sadeghi M; Schemmer P; Encke J; Sauer P; Zeier M; Weitz J; Büchler MW; Schmidt J
Clin Transplant; 2006; 20 Suppl 17():30-43. PubMed ID: 17100699
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
28. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
29. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
30. Clinical application of sirolimus in renal transplantation: an update.
Chueh SC; Kahan BD
Transpl Int; 2005 Mar; 18(3):261-77. PubMed ID: 15730485
[TBL] [Abstract][Full Text] [Related]
31. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
32. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
34. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
Citterio F; Sparacino V; Altieri P; Rigotti P; Calabrese S; Poli M; Vinti V; Segoloni GP
Transplant Proc; 2005 Mar; 37(2):827-9. PubMed ID: 15848545
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
36. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Sparacino V; Calabrese S
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii34-7. PubMed ID: 16815856
[TBL] [Abstract][Full Text] [Related]
37. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
38. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
[TBL] [Abstract][Full Text] [Related]
39. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
Sánchez Fructuoso A; Ruiz San Millán JC; Calvo N; Rodrigo E; Moreno MA; Cotorruelo J; Conesa J; Gómez-Alamillo C; Arias M; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]